Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders [Seeking Alpha]
Nkarta, Inc. (NKTX)
Company Research
Source: Seeking Alpha
Financially healthy, with a high current ratio and a cash runway extending into 2026, indicating low near-term dilution risk. Despite high short interest, market sentiment is robust, driven by insider buying and significant institutional investment. Nkarta is a speculative buy, with potential in autoimmune cell therapies, but faces competition and inherent biotech sector risks. Nkarta's Rally: From Laboratory to Limelight in Cell Therapy Nkarta's NASDAQ: NKTX ) stock is up an astounding 690% within the past six months. Subsequently, the stock is ranked 15 out of 4539 stocks in Seeking Alpha's Quant Ranking. Let's check it out. Nkarta uses cell therapies, specifically natural killer cells (NK cells), to treat cancer and autoimmune conditions. The theorized benefit of NK cells over CAR-T (T cell therapy) therapies is multifold. For one, NK cells are able to target multiple tumor antigens, which may allow improved activity against solid tumors. Two, NK cells pose a lower risk
Show less
Read more
Impact Snapshot
Event Time:
NKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTX alerts
High impacting Nkarta, Inc. news events
Weekly update
A roundup of the hottest topics
NKTX
News
- Nkarta, Inc. (NASDAQ: NKTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.MarketBeat
- Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of InvestorsBusiness Wire
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of InvestorsBusiness Wire
- The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of InvestorsBusiness Wire
- Nkarta to Participate in Upcoming Investor ConferencesGlobeNewswire
NKTX
Earnings
- 3/21/24 - Beat
NKTX
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- NKTX's page on the SEC website